Navigation Links
Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
Date:4/29/2011

NEW YORK, April 29, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease (the "Company"), today announced its results for the first quarter ended March 31, 2011.

At March 31, 2011, the Company had cash, cash equivalents and investment securities of $23.1 million, as compared to $28.5 million at December 31, 2010.  Subsequent to March 31, 2011, the Company received a $5.0 million milestone payment from its Japanese partner for Zerenex (ferric citrate), Japan Tobacco Inc. ("JT") and Torii Pharmaceutical Co., Ltd. ("Torii"), related to JT and Torii's commencement of a Phase 3 clinical program of ferric citrate in Japan.The net loss for the first quarter ended March 31, 2011, was $6.4 million, or $0.10 per share, compared to a net loss of $4.0 million, or $0.07 per share, for the comparable quarter in 2010, representing an increase in net loss of $2.4 million.  Other research and development expenses, for the first quarter ended March 31, 2011, increased by $2.1 million, as compared to the first quarter of 2010, principally related to the KRX-0401 (perifosine) and Zerenex Phase 3 clinical programs.  The net loss for the first quarter ended March 31, 2011, included $0.6 million of non-cash compensation expense related to equity incentive grants.

Commenting on the quarter, Ron Bentsur, the Company's Chief Executive Officer, said, "During the first quarter, we continued to advance our compounds, perifosine and Zerenex, in Phase 3 development."  Ron Bentsur, continued, "We are focused on meeting the key clinical milestones that we have set out to achieve, while remaining operationally efficient with a well-controlled burn rate."

The Company will host an i
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
3. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
4. Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
6. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
7. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
8. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009 Financial Results on Thursday, May 14, 2009 at 8:30am EDT
10. Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology
11. Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , Oct. 1, 2014  Discovery Laboratories, ... has been awarded a Phase II Small Business ... $3.0 million from the National Institute of Allergy ... of Health (NIH) to support the development of ... a medical countermeasure to mitigate acute and chronic/late-phase ...
(Date:10/1/2014)... Switzerland (PRWEB) October 01, 2014 ... the quality of the final product. However, while ... regulated, regulatory frameworks such as Good Manufacturing Practices ... the responsibility of the manufacturer to interpret these ... consistent weighing performance quality. METTLER TOLEDO experts have ...
(Date:10/1/2014)... Pfanstiehl has announced the launch of ... the USA under ICH ... for playing a key role in protein glycosylation.  ... that media supplementation with mannose can improve overall ... to Dr. Christopher Wilcox , VP, Business ...
(Date:10/1/2014)... (PRWEB) September 30, 2014 The participants ... designs, but to spending their own time adjusting, tweaking ... their complex designs were ready for judging. , “I ... design firm thought leader. “The entries showed a ... the physical characteristics of the print medium and the ...
Breaking Biology Technology:Discovery Labs Receives SBIR Grant Valued up to $3.0 Million to Support Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives SBIR Grant Valued up to $3.0 Million to Support Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3Comply with Weighing-Related Regulations in Pharma Manufacturing 2Pfanstiehl Launches cGMP-produced Mannose for Cell Culture Media Optimization & Glycoprotein Biosynthesis 2Array Architects Challenges Staff to Create with 3D Printer 2
... Much of Thursday's Digital Healthcare Conference ... facing plenty of them. , ,In today's issue, the ... from the Digital Healthcare Conference, you'll read about the ... are approaching those choices. Next issue, look for coverage ...
... to the north. The country brings to mind Mounties and ... Vancouver, British Columbia supports a thriving technology development environment, and ... a week there recently, meeting with some very savvy developers. ... some of the companies I met there. , , Imagis ...
... Brookfield-based Fiserv, Inc. , has ... management and billing software for large and mid-sized ... ,Interactive Technologies, headquartered in Summit, New Jersy, develops ... management companies, depositories, exchanges and other high-end providers ...
Cached Biology Technology:The tough choices facing health care 2The tough choices facing health care 3Imagis emerges from bumpy road 2Imagis emerges from bumpy road 3
(Date:9/30/2014)... Mediterranean each year, but its deep-blue waters host ... 1,000 alien species, including fish, crustaceans, and algae ... activities. In the open-access journal Frontiers in ... analyzed data from a new information system developed ... introduction of alien species has changed the native ...
(Date:9/30/2014)... Engineers at the University of California, San Diego, have ... tissue using a method that uses the pixels in ... method known as mesh-free simulation. , The researchers, led ... engineering at the Jacobs School of Engineering at UC ... this method at the CompIMAGE,14 conference in Pittsburgh this ...
(Date:9/30/2014)... assessment conducted by the Ocean Health Index rates ... in overall health. In addition, for the first ... 15 ocean regions beyond national jurisdiction (high-seas areas) ... climate, safeguarding biodiversity and providing sustainable food sources. ... index, a partnership led by scientists from UC ...
Breaking Biology News(10 mins):Biodiversity in the Mediterranean is threatened by alien species 2First comprehensive meshfree numerical simulation of skeletal muscle tissue achieved 2Rating the planet's oceans 2Rating the planet's oceans 3
... painful relationship with Campylobacter jejuni, we are just starting ... the leading cause of bacterial food-borne illness in the ... of diarrhea worldwide. The Centers for Disease Control estimate ... , While most sufferers recover after a few unpleasant ...
... University in Ithaca and Weill Cornell Medical College in ... protein biomarkers in cerebrospinal fluid that acts as a ... patients living with Alzheimer's disease. , The research will ... Annals of Neurology. , Right now, physicians ...
... 2006 -- A new study in Journal of the World ... smaller shrimp of the same gender when competing for food, ... adult males of the species are typically much smaller than ... and gender are important factors in acquiring food," says study ...
Cached Biology News:The biggest bug in gut discomfort 2Protein 'fingerprint' in spinal fluid could spot Alzheimer's disease 2Protein 'fingerprint' in spinal fluid could spot Alzheimer's disease 3
... Terminal deoxynucleotidyl transferase (TdT) is an ... in cortical thymocytes and minor subpopulation of ... enzyme and increased numbers of TdT cells ... lymphoblastic leukaemias and lymphomas. Presence of TdT ...
Request Info...
... The RapidStak is a fast ... its class. Its high capacity ... and more confident walk away time ... and ease of set-up make for ...
... to MLF1 Interacting Protein/PBIP1 (phospho T78) ... applications). Antigen: ... acids 73-83 of Human MLF1 Interacting ... ID: 359815 ...
Biology Products: